SCHEMBL7809181

SCHEMBL7809181

Cc1cccc(C)c1NC(=O)CNCCCCNCCC(O)Cc1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.48
HTT P42858 1/20 0.48
CYP2C9 P11712 3/20 0.44
CYP3A4 P08684 2/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
ALOX12 P18054 2/20 0.40
CYP1A2 P05177 2/20 0.40
CYP2C19 P33261 2/20 0.40
HDAC3 O15379 1/20 0.40
HDAC4 P56524 1/20 0.40
HDAC1 Q13547 1/20 0.40
HDAC7 Q8WUI4 1/20 0.40
HDAC2 Q92769 1/20 0.40
HDAC10 Q969S8 1/20 0.40
HDAC11 Q96DB2 1/20 0.40
HDAC8 Q9BY41 1/20 0.40
HDAC6 Q9UBN7 1/20 0.40
HDAC9 Q9UKV0 1/20 0.40
HDAC5 Q9UQL6 1/20 0.40
RECQL P46063 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7114567 0.84 TDP1 (0.46) ALDH1A1HTTCYP2C9CYP3A4SMN1; SMN2
SCHEMBL7119702 0.81 PKM (0.48) ALDH1A1HTTCYP3A4MEN1KMT2A
SCHEMBL7809317 0.77 TSHR (0.60) ALDH1A1CYP3A4SMN1; SMN2CYP1A2MEN1
SCHEMBL11873259 0.76 GAA (0.58) ALDH1A1HTTCYP2C9CYP3A4CYP1A2
SCHEMBL25138828 0.75 ALDH1A1 (0.78) ALDH1A1HTTCYP2C9CYP3A4SMN1; SMN2
SCHEMBL11872043 0.75 GAA (0.64) ALDH1A1HTTCYP2C9CYP3A4SMN1; SMN2
SCHEMBL22781757 0.73 HDAC3 (0.48) ALDH1A1HTTCYP2C9CYP3A4SMN1; SMN2
SCHEMBL22781784 0.73 HDAC3 (0.48) ALDH1A1HTTCYP2C9CYP3A4SMN1; SMN2
SCHEMBL9678663 0.72 GAA (0.50) ALDH1A1HTTCYP2C9CYP3A4CYP1A2
SCHEMBL9678655 0.72 GAA (0.50) ALDH1A1HTTCYP2C9CYP3A4CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20010036961-A1 Substituted alkylene diamine compounds CV THERAPEUTICS, INC. 2001-11-01 US claimed
WO-2001062711-A2 SUBSTITUTED ALKYLENE DIAMINE COMPOUNDS CV THERAPEUTICS, INC. (US) 2001-08-30 WO claimed
US-20010036961-A1 Substituted alkylene diamine compounds CV THERAPEUTICS, INC. 2001-11-01 US disclosed
WO-2001062711-A2 SUBSTITUTED ALKYLENE DIAMINE COMPOUNDS CV THERAPEUTICS, INC. (US) 2001-08-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010036961-A1 Substituted alkylene diamine compounds TNNC1, CPT1B, TNNI3 ALDH1A1 37/4885HTT 4829/4885CYP2C9 2128/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.